News Article

DxTerity Diagnostics Inc. Acquires Gene Signature Portfolio from SourceMDx Inc.
Date: Jun 07, 2011
Author: press release
Source: Business Wire ( click here to go to the source)

Featured firm in this article: DxTerity Diagnostics Inc of Rancho Dominguez, CA

LOS ANGELES--(BUSINESS WIRE)--DxTerity Diagnostics announced today that it has acquired intellectual property rights to several blood based cancer diagnostic tests from SourceMDx Inc. These tests include blood based gene expression assays for the early diagnosis of Breast and Lung cancer, as well as a blood based test for determining survival and therapy response in Melanoma. These tests are protected by a broad portfolio of over 30 US and International patent filings.

DxTerity has begun the process of migrating these tests to its revolutionary NEAT (Non-Enzymatic Amplification Technology) platform. According to Dr. Bob Terbrueggen, CEO of DxTerity Diagnostics, "The NEAT platform is perfect for blood based genomic testing since it enables the simultaneous direct from sample measurement of up to 40 gene targets. The Breast, Lung and Melanoma tests represent significant steps forward in the treatment of life threatening diseases, and DxTerity's technology enables the low-cost delivery of these tests." The terms of the agreement were not disclosed.

About DxTerity Diagnostics Inc.

DxTerity Diagnostics ( is an emerging genomics company that has developed a revolutionary medical device that allows technicians to run complex genomic tests in one hour in the doctor's office. DxTerity's core technology platform is known as NEAT™ or Non-Enzymatic Amplification Technology. NEAT™ based Solutions enable the low-cost delivery of high value Genomic tests at the point-of-care.

About SourceMDx Inc.

SourceMDx® is the first diagnostic company to establish that a "White Blood Cell Biopsy" from whole blood can consistently provide a diagnostic signal in cancer patients by measurement of gene expression for early detection, disease aggressiveness and survival prognosis in a reproducible fashion. The Company established a broad patent portfolio as a result of over 150 pre-clinical projects and clinical trials with leading academic medical centers and pharmaceutical companies.

Keywords: DxTerity, Diagnostics, point-of-care, molecular, Breast cancer, Lung cancer, Melanoma, blood based test, NEAT platform, Non-Enzymatic, Genomic, Genetic, Sample to Answer

DxTerity Diagnostics
Dr. Bob Terbrueggen, 310-537-7857